Valuation : Valneva SE

Market Cap 539M 628M 506M 462M 871M 59.85B 876M 5.98B 2.32B 30.19B 2.36B 2.3B 100B P/E 2026 *
-6.52x
P/E 2027 * 10.3x
Enterprise Value 672M 783M 631M 576M 1.09B 74.71B 1.09B 7.47B 2.89B 37.69B 2.94B 2.88B 125B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 2.12x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.49%
1 week-2.46%
Current month+32.87%
1 month+32.37%
3 months+6.22%
6 months-39.66%
Current year-23.24%
1 week 2.78
Extreme 2.783
2.99
1 month 2.12
Extreme 2.121
3.24
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.34
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Date Insider Type Main position Quantity % Market Cap.
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Fiscal year

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-2.46%-24.38%-55.28% 628M
-0.34%0.00%+2.34%+23.20% 50.96B
+1.92%+0.36%+477.97%+550.09% 46.18B
-0.15%-0.28%+21.65%+89.41% 42.73B
+0.81%+4.91%+39.28%+19.41% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
+0.81%+1.77%+31.91%+138.26% 17.28B
-1.08%-3.61% - - 16.43B
-0.30%-0.38%+11.33%+28.07% 14.73B
-0.85%+1.76%+80.26%+47.26% 14.09B
Average -0.02%+0.99%+72.73%+99.10% 27.95B
Weighted average by Cap. +0.15%+1.15%+103.06%+138.33%

Financials

2026 *2027 *
Net sales 151M 176M 142M 129M 244M 16.78B 245M 1.68B 650M 8.47B 661M 646M 28.04B 283M 330M 266M 243M 458M 31.49B 461M 3.15B 1.22B 15.89B 1.24B 1.21B 52.62B
Net income -81.11M -94.51M -76.13M -69.54M -131M -9.01B -132M -901M -349M -4.55B -355M -347M -15.06B 53.07M 61.83M 49.81M 45.5M 85.86M 5.9B 86.28M 590M 228M 2.98B 232M 227M 9.85B
Net Debt 134M 156M 126M 115M 216M 14.86B 217M 1.49B 576M 7.5B 585M 572M 24.83B 62.48M 72.79M 58.64M 53.56M 101M 6.94B 102M 694M 269M 3.5B 273M 267M 11.6B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
27/08/26 2.854 +0.49% 191,834
26/08/26 €2.840 -1.87% 415,003
25/08/26 €2.894 +0.73% 819,141
24/08/26 €2.873 -3.14% 1,088,589
21/08/26 €2.966 +1.37% 888,987
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.840EUR
Average target price
6.193EUR
Spread / Average Target
+118.06%

Quarterly revenue - Rate of surprise